Pharma company Ranbaxy Laboratories Ltd said its subsidiary Ranbaxy (South Africa) Pvt Ltd has opened its new manufacturing facility, Be-Tabs Pharmaceuticals Manufacturing Plant, at Roodepoort in South Africa
The new facility, built with an investment of $30 million, will manufacture analgesics, cold, cough and flu preparations, anti-histamines, anti-hypertensives, CNS drugs, vitamins and minerals as well as a comprehensive range of over-the-counter medication. The products manufactured will comprise tablets and hard gelatin capsules that will be supplied to current registered regions, Ranbaxy said in a regulatory filing.
On Thursday, Ranbaxy shares rose 1.2% to Rs503 on Bombay Stock Exchange, while the benchmark Sensex closed 0.2% up at 18,238 points.
Sun Pharmaceutical Industries Ltd said it received an approval to sell generic strattera, atomoxetine hydrochloride capsules from the US Food and Drug Administration (USFDA).
Atomoxetine hydrochloride capsules are used to treat hyperactivity disorder.
The company's subsidiary has received abbreviated new drug application approval from the FDA to market generic atomoxetine hydrochloride capsules in strengths of 10mg, 18mg, 25mg, 40mg, 60mg and 100mg in that country, Sun Pharma said in a filing to Bombay Stock Exchange (BSE).
The annual sale for these strengths of branded and generic atomoxetine hydrochloride capsules is estimated at over $530 million in the US.
On Thursday, Sun Pharma shares declined 0.9% to Rs1,735 on BSE, while the benchmark Sensex closed 0.2% up at 18,238 points.
IRB Infrastructure Developers Ltd said its subsidiary signed an agreement with Indian Hotels Company Ltd (IHC) for operating and maintaining its hotel in Kolhapur. No financial details were provided.
According to agreement, IRB's unit Aryan Hospitality Pvt Ltd will set up a Gateway Hotel at Kolhapur in Maharashtra, which would be operated and maintained by IHC.
The proposed hotel will have 100 to 125 guest rooms along with other modern recreation and leisure facilities. The proposed hotel will be constructed within three years, IRB said in a regulatory filing.
On Thursday, IRB Infra shares shed 1.7% to Rs283 on Bombay Stock Exchange, while the benchmark Sensex closed 0.2% up at 18,238 points.